Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma by Gkotzamanidou, Maria et al.
 
Angiogenic cytokines profile in smoldering multiple myeloma:
No difference compared to MGUS but altered compared to
symptomatic myeloma
 
 
(Article begins on next page)
The Harvard community has made this article openly
available.
Please share how this access benefits you. Your story
matters.
Citation Gkotzamanidou, Maria, Dimitrios Christoulas, Vassilis L.
Souliotis, Athanasios Papatheodorou, Meletios A.
Dimopoulos, and Evangelos Terpos. 2013. “Angiogenic
cytokines profile in smoldering multiple myeloma: No
difference compared to MGUS but altered compared to
symptomatic myeloma.” Medical Science Monitor :
International Medical Journal of Experimental and Clinical
Research 19 (1): 1188-1194. doi:10.12659/MSM.889752.
http://dx.doi.org/10.12659/MSM.889752.
Published Version doi:10.12659/MSM.889752
Accessed February 19, 2015 3:04:04 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879398
Terms of Use This article was downloaded from Harvard University's
DASH repository, and is made available under the terms and
conditions applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-
3:HUL.InstRepos:dash.current.terms-of-use#LAAReceived: 2013.09.05
Accepted: 2013.09.23
Published: 2013.12.20
 2120     2     3     29
Angiogenic cytokines profile in smoldering 
multiple myeloma: No difference compared to 
MGUS but altered compared to symptomatic 
myeloma
  ABCDEF 1,2  Maria Gkotzamanidou
  BCDE 1  Dimitrios Christoulas
  ABCEF 3  Vassilis L. Souliotis
  BCDE 4  Athanasios Papatheodorou
  ABCDE 1  Meletios A. Dimopoulos
  ABCDEF 1  Evangelos Terpos
  Corresponding Author:  Evangelos Terpos, e-mail: eterpos@med.uoa.gr or eterpos@hotmail.com
  Source of support:  Departmental sources
  Background:  Symptomatic multiple myeloma (MM) evolves from an asymptomatic precursor state termed monoclonal gam-
mopathy of undetermined significance (MGUS) and smoldering myeloma (SMM). Angiogenesis plays a key role 
in the pathogenesis of MM but there are very limited data for angiogenesis in SMM.
  Material/Methods:  We measured the circulating levels of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), vascular endothelial 
growth factor (VEGF), and angiogenin in 54 patients with SMM. The results were compared with those of 27 
MGUS patients, 55 MM patients, and 22 healthy controls. The expression of VEGF-A gene was also evaluated 
in 10 patients with SMM, 10 with symptomatic MM, and 10 with MGUS.
  Results:  The ratio of circulating Ang-1/Ang-2 was reduced in MM patients with symptomatic disease due to a dramat-
ic increase of Ang-2 (p<0.001), but not in patients with SMM or MGUS, in whom it did not differ compared to 
controls. VEGF and angiogenin were increased in all patients compared to controls. However, circulating VEGF 
was higher in symptomatic MM compared to SMM and MGUS, while angiogenin was reduced. There were no 
differences in the expression of VEGF-A among the 3 patients categories.
  Conclusions:  SMM has a circulating angiogenic cytokine profile similar to that of MGUS, but has altered profile compared to 
symptomatic MM. Thus, in the progression of MGUS to SMM, circulating angiogenic cytokines seem to be the 
same. On the contrary, in symptomatic myeloma, the alterations of angiopoietins along with VEGF contribute 
to myeloma cell growth, supporting the target of these molecules for the development of novel anti-myeloma 
agents.
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Multiple myeloma (MM) is a malignant disorder characterized 
by multifocal proliferation of clonal, long-lived plasma cells 
within the bone marrow (BM). MM presents clinically with a 
broad range of manifestations, including skeletal destruction, 
immune suppression, and end-organ sequelae [1].
The disease accounts for slightly more than 10% of all hemato-
logic cancers [1]. It is estimated that there will be 22 350 new-
ly diagnosed MM cases and 10 710 MM deaths in the United 
States in 2013 [2]. Over the past decade, the outcome of MM 
patients has been dramatically improved after the develop-
ment of novel agents and the introduction of autologous stem 
cell transplantation [3,4]. However, MM remains an incurable 
disease and significant efforts aim to unravel its biology. MM 
is preceded by a premalignant condition termed monoclonal 
gammopathy of undetermined significance (MGUS) [5]. MGUS 
is present in more than 3% of the population above the age of 
50 years. Its annual progression rate to MM is of 0.5% to 3% 
[6]. In some patients, an intermediate but more advanced pre-
malignant stage, termed smoldering multiple myeloma (SMM), 
is clinically recognized [1]. To date, the biological alterations 
that lead from MGUS to SMM and finally to symptomatic dis-
ease have not been elucidated.
MM evolution is characterized by an avascular stage of slow 
tumor progression followed by “angiogenic switch” when the 
balance between pro- and anti-angiogenic factors in the tu-
mor microenvironment is deranged to promote neovascular-
ization and disease progression [7,8]. Angiogenesis is a mul-
tistep and tightly regulated process of the formation of new 
blood vessels, which occurs physiologically during embryonic 
growth and wound healing, but also in tumor growth and me-
tastasis [9,10]. Our previous study elucidated the role of an-
giogenic cytokines in MM pathogenesis, and our results were 
consistence with those of other groups [11–15]. These cyto-
kines mainly include the vascular endothelial growth factor 
(VEGF), the angiogenin, the angiopoietins, and the basic fibro-
blast growth factor (bFGF) [11]. Angiopoietin-1 (Ang-1) and its 
natural antagonist, angiopoietin-2 (Ang-2), are involved in the 
biology of MM. We have shown that the Ang-1 to Ang-2 ratio 
is an independent prognostic factor for survival in newly di-
agnosed MM patients [16,17]. However, to our knowledge, no 
previous studies have evaluated the above angiogenic cyto-
kines in a large population of each of the MM stages.
The aims of this study were to: i) evaluate the circulating lev-
els of important angiogenesis inducers – VEGF-A, angiogenin, 
Ang-1, and Ang-2 – as representative angiogenesis inhibitors 
in patients with MGUS, SMM, and symptomatic MM; and ii) to 
evaluate the gene expression of VEGF-A and determine if any 
variability of this predominant angiogenic cytokine is present 
during the evolutionary process of precursor stages to symp-
tomatic MM, contributing to better understanding the under-
lying mechanisms of this transition.
Material and Methods
Patients and samples processing
We studied 109 consecutive patients, of whom 55 were newly 
diagnosed and symptomatic with MM (n=55), and 54 asymp-
tomatic MM patients (n=54). We also evaluated 27 patients 
with MGUS at diagnosis and, as an internal control group, 22 
healthy controls of similar age and gender (12M/10F; median 
age: 67 years, range: 39–83 years). The study was conducted 
after approval from the institutional Ethical Committee and 
under the guidelines of the Declaration of Helsinki. All patients 
provided written consent for participating in this study. The 
medical history of all subgroups was reviewed to ensure that 
there was no disease (e.g., cardiovascular disorder, inflamma-
tory disease, renal impairment, or infection) or drug adminis-
tration that could alter angiogenesis at the time of sampling. 
Serum samples were collected at the time of diagnosis from all 
patients, before the initiation of any antimyeloma treatment, 
including supportive treatment (e.g., bisphosphonate admin-
istration) and stored at −80°C until the day of measurement. 
Patient and control group characteristics are depicted in Table 1.
Peripheral blood mononuclear cells (PBMCs) and plasma cells 
from bone marrow aspirates used in gene expression study 
were isolated according to previously described standard meth-
ods [18]. Briefly, PBMCs were isolated by using Ficoll-plaque 
density sedimentation from freshly drawn peripheral blood as 
previously described [18]. MM plasma cells from bone marrow 
aspirates were purified by positive selection with anti-CD138 
magnetic activated cell-sorting (MACS) separation microbeads, 
as described by the manufacturer (MACS, Miltenyi Biotec, 
Auburn, CA). Purity, as confirmed by flow cytometry CD38 and 
CD45 staining (FACSCalibur cytometer), was above 95% in 
all MGUS and MM cases, and above 90% in all MM patients.
The gene expression of VEGF-A in PBMCs and in MM plasma 
cells was estimated in a total of 10 patients with MGUS, 10 
patients with SMM, and 10 patients with symptomatic MM. 
The gene expression of VEGF-A in PBMCs was also studied in 
10 healthy volunteers.
ELISA	assay	and	reagents
Circulating levels of Ang-1, Ang-2, VEGF, and angiogenin were 
evaluated in all patients, using an ELISA methodology (R&D 
Systems, Minneapolis, MN,), according to the manufacturer’s 
instructions.
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RNA was extracted from peripheral blood lymphocytes as de-
scribed previously [19]. Total RNA was extracted with Trizol 
according to the manufacturer’s instructions (Invitrogen) and 
purified from salts and residual DNA using the RNease Mini 
Kit (Qiagen). Quantity of RNA in each sample was measured 
by spectroscopy and integrity was determined by gel electro-
phoresis. Only RNAs with clear 18S and 28S peaks were used. 
VEGF-A expression was studied using semi-quantitative RT-PCR 
as described previously [15]. Briefly, RT-PCR was performed as 
a multiplex using the Titan One Tube RT-PCR System according 
to the manufacturer’s instructions (Roche Diagnostics GmbH, 
Mannheim Germany). Following RT-PCR, the samples were 
treated with ExoSAP-IT to remove excess primer and deoxyri-
bonucleotides (dNTPs; USB), as described by the manufactur-
er. A portion of the RT-PCR product was used in the Fast Start 
DNA Master SYBR Green I kit. This reaction was run on the 
Light-Cycler (Roche Diagnostics GmbH) until a sample reached 
plateau stage. PCR products were run on 1% agarose gel, and 
relative quantification was performed by spot densitometry 
comparisons with GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) bands. Expression was quantified as a ratio of cy-
tokine to GAPDH mRNA expression. Primer sequences were 
as follows: for GAPDH, forward 5’-ACCACAGTCCATGCCATCAC-3’ 
and reverse 5’-TCCACCACCCTGTTGCTTGTA-3’; for VEGF-A, 
forward 5’-GCCCACTGAGGAGTCCAACATC-3’ and reverse 
5’-TTTTTGCAGGAACATTTACACG-3’. Melting curve analysis of 
the PCR products was performed to confirm the presence of 
a single specific amplicon.
Statistical analysis
Descriptive statistics were used to characterize baseline vari-
ables. Differences between patients and controls, as well as 
between different patient subsets, were evaluated using the 
Mann-Whitney U test. Spearman’s nonparametric correlation 
test was used to determine the correlations between evaluat-
ed parameters. All p values were 2-sided and the level of sig-
nificance was <0.05.
Results
Measurement of serum levels of angiogenic cytokines
Symptomatic MM patients at diagnosis showed increased lev-
els of serum Ang-2 (mean value ±SD: 5271±3370 pg/ml) com-
pared with SMM patients (2043±1881pg/ml; P<0.001), MGUS 
patients (1851±1516pg/ml; P<0.001), and healthy controls 
(2149±1756 pg/ml, P<0.001). There was no statistically sig-
nificant difference between asymptomatic patients, MGUS 
patients, and controls (Figure 1A). There was no difference in 
circulating levels of ang-1 between patients with MM, SMM, 
MGUS, and healthy controls (Table 2). Consequently, the ang-
1/ang-2 ratio was reduced in symptomatic MM patients (mean 
value ±SD: 8.0±7.3) compared to SMM patients (19.8±12.3; 
P<0.001), MGUS patients (22.2±15.3; p<0.001), and healthy 
controls (18.0±16.6; P<0.001), but there was no significant dif-
ference between asymptomatic patients, MGUS patients, and 
controls (Figure 1B). Serum levels of VEGF were increased in 
MM SMM MGUS
No 54 55 27
Gender (M/F) 30/24 29/26 15/12
Median age (range) 66(34–80) 65 (38–85) 67 (43–86)
Ig-subtype IgG 67%
IgA 15%
Light chain 18%
IgG 72%
IgA 28%
IgG 63%
IgA 31%
Light chain 6%
ISS-stage I 39%
II 38%
III 23%
I 100%
Hb <10 g/Dl 32% 0 0
Creatinine >UNL 18% 3.6% 3.7%
Creatinine ≥2 mg/dl 9% 0 0
Albumin <3.5 g/Dl 19% 0 0
b2-M >6 mg/L 16% 0 0
Table 1. Patient characteristics.
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pg/ml; P=0.04), and MM (613±408 pg/ml; P=0.001) compared 
to healthy controls (286±267 pg/ml). Patients with MM had in-
creased VEGF serum levels compared to MGUS and SMM pa-
tients (P=0.039 and P=0.009, respectively (Figure 2A). Patients 
with MGUS, SMM, and symptomatic MM had increased lev-
els of serum angiogenin (379.9±155.6 ng/ml, 377.1±137.8 
ng/ml and 255.6±137.2 pg/ml, respectively) compared with 
the healthy controls (165.1±34.3 ng/ml; P<0.001 for all com-
parisons). Patients with MM had decreased angiogenin serum 
levels compared to MGUS and SMM patients (P<0.001) for both 
comparisons. There was no statistically significant difference 
between SMM and MGUS patients (Figure 2B). A trend was ob-
served in the correlation of angiogenin serum levels with ang-2 
(r=–0.250, P=0.008) and Ang-1/Ang-2 ratio (r=0.217, P=0.022).
VEGF-A	expression	by	semi-quantitative	RT-PCR
We found that VEGF-A is expressed in PBMCs and MM plas-
ma cells from all patients in all groups analyzed. In PBMCs, 
we observed no significant difference in the levels of VEGF-A 
mRNA expression between healthy volunteers, MGUS, SMM, 
and MM patients, with median ±SD VEGF-A/GAPDH ratios of 
1.019±0.081, 1.087±0.093, 1.116±0.091 and 1.119±0.109, re-
spectively. Similarly, no difference in the levels of VEGF-A ex-
pression was observed in MM plasma cells among the 3 pa-
tients groups, with median ±SD VEGF-A/GAPDH ratios of 
0.933±0.1322, 1.028±0.1279, and 0.973±0.1406, respective-
ly (Figure 3).
Discussion
Several cytokines are implicated in the angiogenesis process. 
The cross-talk among angiogenic and inflammatory cytokines 
plays an important role in the modulation of blood vessel 
growth in several pathological conditions, including cancer. In 
the abnormal tumor microenvironment, pro-angiogenic cyto-
kines and inflammatory mediators prevail and promote struc-
turally and functionally aberrant vessel formation [7]. During 
tumor angiogenesis, Ang-2 antagonizes Tie2 binding and de-
stabilizes the vessel wall of mature vessels. Quiescent endo-
thelial cells become sensitive to VEGF, then proliferate and mi-
grate to form new vessels. Bone marrow-derived endothelial 
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Figure 1.   Circulating angiopoietin-2 (A) and ratio of angiopoietin-1/angiopoietin-2 (B) in patients and controls.
Ang-1	(ng/ml) Ang-2	(ng/ml) Ang-1/Ang-2 VEGF	(pg/ml) ANG	(ng/ml)
Healthy controls (n=22)
(mean value ±SD)
 23.3±11.9  2.1±1.8  18.0±16.6  286±267  165.1±34.3
MGUS patients (n=27)
(mean value ±SD)
 29.6±9.9  1.8±1.5  22.2±15.3  399±188  379.9±155.6
SMM patients (n=54)
(mean value ±SD)
 27.4±7.9  2.0±1.9  19.8±12.3  403±273  377.1±137.8
MM patients (n=55)
(mean value ±SD)
 26.4±13.7  5.3±3.4  8.0±7.3  613±408  255.6±137.2
Table 2. Levels of circulating angiogenic cytokines in patients and controls.
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cruited by angiogenin at sites of angiogenesis [20–23].
MM was the first hematologic malignancy in which angiogen-
esis were defined as a prognostic factor [24,25]. Vacca et al. 
first demonstrated that tumor growth is angiogenesis-depen-
dent [26], by reporting a high correlation between the extent 
of BM angiogenesis (microvessel area) and the proliferating 
fraction of BM plasma cells (labeling index) in MGUS and MM 
patients. Angiogenesis itself was significantly associated with 
active, as opposed to non-active, MM and MGUS [26].
Angiogenesis is possibly important in the progression of MGUS 
to MM and in the progression of early-stage myeloma to ad-
vanced, refractory disease. Previous reports have shown that 
bone marrow angiogenesis progressively increases along the 
spectrum of plasma cell disorders, from the more benign stage 
of MGUS to advanced myeloma, indicating that angiogenesis 
may be related to disease progression [8]. A proposed mech-
anism is that angiogenesis contributes to myeloma pathogen-
esis and progression by ensuring an adequate tumor oxygen 
and nutrient supply and by paracrine stimulation of tumor cell 
migration and proliferation [27]. However, the precise mecha-
nism underlying the observed alterations of angiogenic cyto-
kines in the evolution of MM has not been fully investigated; 
our study aimed to answer this critical question.
VEGF was increased in the serum of patients with MM as well 
as in patients with MGUS and SMM compared with healthy 
control samples, indicating that myeloma genesis, the transi-
tion process to symptomatic disease, occurs via mechanisms 
that are less VEGF-dependent. Nevertheless, patients with 
symptomatic disease had higher VEGF serum levels than oth-
er patients, perhaps due to greater tumor burden. However, 
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Figure 2.   Circulating VEGF (A) and angiogenin (B) in patients and controls.
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Figure 3.   VEGF-A expression by PBMCs (A) and plasma cells (B) in different patient groups.
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Mrna, induction of translation and stabilization of final pro-
tein could be responsible, since we found no significant dif-
ference in the levels of VEGF-A mRNA expression from plas-
ma cells of MGUS, SMM, and MM patients.
Reduced angiopoietin-1/angiopoietin-2 ratio has been pre-
viously correlated with advanced disease features, including 
international staging system (ISS)-3 stage, renal impairment, 
b2-microglobulin levels, and extensive bone disease, as well 
as with inferior survival in newly diagnosed patients with MM 
who received therapy with novel antimyeloma agents [17,28]. 
In the present study, symptomatic MM patients, but not MGUS 
or SMM patients, had increased serum levels of ang-2 and de-
creased ang-1/ang-2 ratio compared with healthy controls. 
These results highlight the role of angiopoietins’ pathway in 
the biology of symptomatic disease.
Interestingly, the patients with symptomatic MM exhibit de-
creased serum levels of angiogenin compared to MGUS and 
SMM patients, but had increased levels compared to healthy 
controls. The observed negative correlation between angio-
genin and Ang-2 is a novel and intriguing finding.
Furthermore, it is well established that there is a widespread 
expression pattern of angiogenin, suggesting a physiological 
function that is not restricted to the neovascularization pro-
cess [29]. Further investigation is needed to unravel the com-
plex network of angiogenic cytokines and their precise role in 
the biology of MM.
Conclusions
Patients with SMM have similar levels of circulating angiopoi-
etins, angiogenin, and VEGF compared with MGUS patients, 
but these levels are altered compared to symptomatic MM pa-
tients. Ang-1/Ang-2 and angiogenin is reduced in MM patients 
with symptomatic disease compared to MGUS or SMM. These 
results suggest that in the progression of MGUS to SMM, cir-
culating angiogenic molecules appear to be the same. In con-
trast, in symptomatic disease the alterations of angiopoietins’ 
pathway along with VEGF contribute to myeloma cell growth. 
Because there is great need for novel drugs active against my-
eloma cells, our data support that the Ang-1/Ang-2/Tie-2 axis 
may be an effective target for the development of novel an-
timyeloma agents.
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